Abstract
The persistence of latent viral reservoirs remains the major obstacle to eradicating human immunodeficiency virus (HIV). We herein reported that recombinant herpes simplex virus type I (HSV-1) with ICP34.5 deletion could more effectively reactivate HIV latency than its wild-type counterpart. Mechanistically, HSV-ΔICP34.5 promoted the phosphorylation of HSF1 by decreasing the recruitment of protein phosphatase 1 (PP1α), thus effectively binding to the HIV LTR to reactivate the latent reservoirs. In addition, HSV-ΔICP34.5 enhanced the phosphorylation of IKKα/β through the degradation of IκBα, leading to p65 accumulation in the nucleus to elicit NF-κB pathway-dependent reactivation of HIV latency. Then, we constructed the recombinant HSV-ΔICP34.5 expressing simian immunodeficiency virus (SIV) env, gag, or the fusion antigen sPD1-SIVgag as an HIV therapeutic vaccine, aiming to achieve a functional cure by simultaneously reactivating viral latency and eliciting antigen-specific immune responses. Results showed that these constructs effectively elicited SIV-specific immune responses, reactivated SIV latency, and delayed viral rebound after the interruption of antiretroviral therapy (ART) in chronically SIV-infected rhesus macaques. Collectively, these findings provide insights into the rational design of HSV-vectored therapeutic strategies for pursuing an HIV functional cure.
Introduction
The epidemic of acquired immunodeficiency syndrome (AIDS), caused by human immunodeficiency virus type I (HIV-1), is still a huge challenge for global public health, with approximately 39 million people living with HIV-1 as of 2022. To date, there is neither a curable drug nor a prophylactic vaccine for clinical use against HIV-1 infections. Antiretroviral therapy (ART) can effectively control HIV-1 replication to an undetectable level, but the termination of ART usually results in prompt viral rebound from latent viral reservoirs (Archin et al., 2014, Looker et al., 2017, Calistri et al., 2003, Heng et al., 1994). Thus, it is of great priority to explore novel strategies for curing HIV latency. The “Shock and Kill” strategy is considered a promising approach for purging HIV-1 reservoirs, involving the activation of latently infected cells to express viral products (Shock), followed by viral cytopathic effects or specific cytolytic T lymphocytes (CTLs) to eliminate the activated cells (Kill) (Wu et al., 2022, Yang et al., 2019, Kim et al., 2018). Numerous latency-reversing agents (LRAs) (Yang et al., 2019, Wu et al., 2022), including methylation inhibitors, histone deacetylase (HADC) inhibitors (Archin et al., 2017, Lehrman et al., 2005), and bromodomain and extra terminal domain (BET) protein inhibitors (Li et al., 2013, Bisgrove et al., 2007), have been identified to reactivate latent HIV-1 in preclinical studies, but there is no ideal LRA available for clinical patients yet.
Herpes simplex virus (HSV), a human herpesvirus, features a 152-kb double-stranded DNA genome encoding over 80 proteins (Poh, 2016). Owing to its distinctive genetic background, high capacity, broad tropism, thermostability, and excellent safety profile, modified HSV variants have found extensive applications in gene therapy and oncolytic virotherapy. For example, talimogene laherparepvec (T-VEC), an HSV-1 variant with ICP34.5 deletion and GM-CSF insertion, received FDA approval in 2015 for treating malignant melanoma, showcasing notable safety and efficacy in clinical practice. Recombinant HSV-based constructs have also emerged as efficacious gene delivery vectors against infectious diseases. Early studies indicated that prophylactic vaccines based on HSV, expressing simian immunodeficiency virus (SIV) antigens, could elicit robust antigen-specific CTL responses in mice and monkeys, providing enduring and partial protection against pathogenic SIVmac239 challenges (Kaur et al., 2007, Murphy et al., 2000). Moreover, increasing data suggest the crucial role of HIV-specific CTL in controlling viral replication and eliminating potential HIV reservoirs (Collins et al., 2020, Leitman et al., 2017). Significantly, epidemiological research suggests a synergistic effect between HSV and HIV infections, with HSV infection in HIV patients being associated with increased HIV-1 viral load and disease progression (Looker et al., 2017, Calistri et al., 2003, Heng et al., 1994). Some studies have further unveiled the ability of HSV to activate HIV latent reservoirs (Amici et al., 2004, Amici et al., 2001, Pierce et al., 2023). Given the potential of HSV to simultaneously induce antigen-specific immune responses and reactivate latent viral reservoirs, we propose a proof-of-concept strategy to achieve an HIV functional cure using a modified bifunctional HSV-vectored therapeutic vaccine.
Results
The modified HSV-ΔICP34.5-based constructs reactivated HIV latency more efficiently than wild-type HSV counterparts
The J-Lat 10.6 cell line, originating from Jurkat T cells with latent HIV-1 provirus, was infected with wild-type HSV-1 17 strain (HSV-wt) at different multiplicities of infection (MOI) to assess its capability to reactivate HIV latency. Flow cytometry analysis showed that green fluorescent protein (GFP) expression was increased in a dose-dependent manner (Figure 1A), and the mRNA levels of HIV-1 LTR, Tat, Gag, Vif, and Vpr were also significantly increased in response to HSV stimulation (Figure 1B), demonstrating that the latent HIV provirus can be reactivated to a certain extent by wild-type HSV. In addition, different HSV-1 strains, including HSV-1 Mckrae and HSV-1 F strain, can also reactivate HIV latency (Figure 1 - figure supplement 1). Remarkably, we found for the first time that the HSV-1 17 strain with ICP34.5 deletion (HSV-ΔICP34.5) could reactivate HIV latency more efficiently than HSV-wt. Specifically, the mRNA levels of HIV genes (LTR, Tat, Gag, Vpr, Vif) were substantially increased in HSV-ΔICP34.5-infected J-Lat 10.6 cells than in HSV-wt treated cells, although there was a weaker replication ability of HSV-ΔICP34.5 in these cells than that of HSV-wt, as indicated by the mRNA level of HSV UL27 (Figure 1C and D). Furthermore, this finding was verified in ACH-2 cells, derived from T cells latently infected with replication-competent HIV-1. A significantly higher level of p24 protein, a key indicator of HIV replication, was found in the HSV-ΔICP34.5-infected ACH-2 cells than in the HSV-wt treated cells (Figure 1E), and the mRNA levels of HIV-1-related genes (LTR, Tat, Gag, Vpr, Vif) were also significantly increased (Figure 1F). Subsequently, we generated J-Lat 10.6 cells stably expressing ICP34.5-Flag-Tag (J-Lat 10.6-ICP34.5) using the recombinant lentivirus system and confirmed the expression of the ICP34.5 protein (Figure 1G). Our research revealed that HSV-ΔICP34.5 displayed reduced reversal capacity for the latent HIV reservoir in J-Lat 10.6-ICP34.5 cells compared to J-Lat 10.6 cells (Figure 1G). Furthermore, in J-Lat 10.6-ICP34.5 cells, the potency of latent reversal agents like phorbol 12-myristate 13-acetate (PMA) and TNF-α was notably reduced when contrasted with J-Lat 10.6 cells (Figure 1H). These findings indicate that HSV ICP34.5 can effectively inhibit the reactivation of the HIV latency, and HSV constructs lacking ICP34.5 potentially reactivate HIV latency with high efficiency.
The modified HSV-based constructs effectively reactivated HIV latency by modulating the IKKα/β-NF-κB pathway and PP1-HSF1 pathway
Next, the mechanism of potentially reactivating viral latency by the modified HSV-ΔICP34.5-based constructs was explored. J-Lat10.6 cells were infected with HSV-wt and HSV-ΔICP34.5, and our results showed that HSV-ΔICP34.5 significantly enhanced the phosphorylation of IKKα/β, promoted the degradation of IKBα, and thus led to the accumulation of p65 in the nucleus (Figure 2A). NF-κB is a well-known host transcription factor that exists in the form of the NF-κB-IκB complex in resting cells, but IκB can degrade and release the NF-κB dimer to enter the nucleus and promote gene transcription in response to external stimulation. Using the coimmunoprecipitation (Co-IP) assay, we verified that the ICP34.5 protein had a specific interaction with IKKα/β, and then ICP34.5 could dephosphorylate IKKα/β. Moreover, the overexpression of ICP34.5 effectively inhibited lipopolysaccharide (LPS) -induced NF-κB pathway activation by inhibiting p65 entry into the nucleus (Figure 2B-C).
To further clarify the underlying mechanism, we next performed the IP-MS assay to identify other potential molecules contributing to this reactivation in J-Lat 10.6-ICP34.5 overexpressing cells, and we found that ICP34.5 can also interact with heat shock 1 protein (HSF1) (table supplement 1). HSF1 has been reported as a transcription factor correlated with the reactivation of HIV latency (Xu et al., 2022, Lin et al., 2018, Zeng et al., 2017). To test whether HSF1 contributes to the reactivation of HIV latency by HSV-ΔICP34.5-based constructs, KRIBB11, an inhibitor of HSF1, was administered to HSV-ΔICP34.5-infected J-Lat 10.6 cells. The results indicated that the reactivation ability of HSV-ΔICP34.5 was significantly inhibited by KRIBB11 treatment in a dose-dependent manner (Figure 2D and E). Furthermore, a significant enhancement of the binding of HSF1 to the HIV LTR was observed upon HSV-ΔICP34.5 infection, leading to an increase in the reactivation of HIV latency (Figure 2F). The direct interaction between ICP34.5 and HSF1 was also identified by Co-IP assay. Importantly, HSF1 was effectively dephosphorylated at Ser320 as a result of the overexpression of ICP34.5, while no influence on the mRNA or protein expression of HSF1 was observed (Figure 2, G and H, Figure 2-figure supplement 2). Considering that protein phosphatase 1 (PP1) can interact with ICP34.5 and dephosphorylate eIF2α (Li et al., 2011), we then investigated the interaction between PP1α and ICP34.5 (Figure 2I). Additionally, a direct interaction between PP1α and HSF1 was found (Figure 2J-L), allowing for the dephosphorylation of HSF1 and then affecting its ability to reactivate HIV latency.
Collectively, these findings demonstrated that our modified HSV-ΔICP34.5-based constructs effectively reactivated HIV latency by modulating the IKKα/β-NF-κB pathway and PP1-HSF1 pathway.
Construction of recombinant HSV-1 expressing exogenous SIV genes elicited robust immune responses in mice
Prior research suggested that HSV-ΔICP34.5 holds significant promise in reactivating latent HIV efficiently. Subsequently, we explored the potential of advancing HSV-ΔICP34.5 as a bifunctional therapeutic vector to revive latent viral reservoirs and inducing antigen-specific immune responses against chronic HIV infection. To achieve this, the HSV-1 ICP34.5 gene was selectively knocked out, and exogenous antigens were introduced using the bacterial artificial chromosome (BAC)/galactokinase (galK) selection system. Additionally, the ICP47 gene was ablated to augment the immunogenicity of the HSV vector (Figure 3A, Figure 3-figure supplement 3). A series of recombinant HSV-ΔICP34.5ΔICP47-based vectors expressing SIV gag and env antigen were constructed, and the antigen expression of these constructs was confirmed by Western blotting assay (Figure 3B and C). Furthermore, to improve the immunogenicity of the targeted antigen, we fused the SIV gag with soluble PD1 (sPD1), enabling it to competitively bind with PD-L1 and thereby block the PD1/PD-L1 immune inhibitory pathway (Figure 3D). Consistent with the above findings, these HSV-ΔICP34.5ΔICP47-based SIV vaccines also efficiently reactivated latent HIV proviruses (Figure 3-figure supplement 4). Then, the immunogenicity of the above modified HSV-ΔICP34.5ΔICP47-based SIV vaccine was assessed in mice (Figure 3E). Our results showed that these constructs effectively elicited SIV antigen-specific T cell immune responses using the interferon γ (IFN-γ) ELISpot assay and the intracellular cytokine staining (ICS) assay (Figure 3F-M). Of note, the frequency of SIV Gag-specific IFN-γ -secreting spot-forming cells (SFCs) in the HSV-sPD1-SIVgag group (1350 SFCs per 106 splenocytes) was significantly higher than that in the HSV-SIVgag group (498 SFCs per 106 splenocytes) (Figure 3F). The frequency of SIV Env2-specific IFN-γ -secreting SFCs in the HSV-SIVenv group was significantly higher than the HSV-empty group (Figure 3G). Furthermore, the functionality of antigen-specific T cell subsets in response to SIV antigen stimulation was confirmed using the ICS assay (Figure 3H-M). Consistently, the HSV-sPD1-SIVgag group showed a significantly higher frequency of SIV-specific CD3+ T, CD4+ T, and CD8+ T cell subsets secreting IFN-γ, IL-2, and TNF-α cytokines compared to the HSV-SIVgag group (Figure 3I-K). Notably, a heightened proportion of Gag-specific effector memory T cells (Tem) of CD8+ T cell subset was observed in comparison to the HSV-Gag group (Figure 3L). In addition, a higher frequency of SIV-Env2-specific CD4+ T cells secreting IFN-γ was observed in the HSV-SIVenv group than in the HSV-empty group (Figure 3M). These data indicated that the vaccines constructed in this study elicit a T cell immune response in mice. Moreover, the blockade of PD1/PDL1 signaling pathway effectively enhanced vaccine-induced T cell immune responses, which was consistent with our and other previous studies (Zhou et al., 2013, Wu et al., 2022, Pan et al., 2018, Xiao et al., 2014).
The modified HSV-based constructs efficiently elicited SIV-specific immune responses in chronically SIV-infected macaques
Next, the immunogenicity of these HSV-vectored SIV vaccines was further investigated in chronically SIVmac239-infected rhesus macaques (RMs). To mimic chronically infected HIV patients in clinic practice, all RMs used in this study were chronically infected with SIV and received ART treatment for several years, as reported in our previous studies (Pan et al., 2018, Yang et al., 2019, Wu et al., 2021, Wu et al., 2022, He et al., 2023). Based on sex, age, viral load, and CD4 count, nine RMs were assigned into three groups: ART+saline group (n=3), ART+HSV-empty group (n=3), and ART+HSV-sPD1-SIVgag/SIVenv group (n=3). All RMs received ART (FTC/6.7 mg/kg/once daily, PMPA/10 mg/kg/once daily) treatment to avoid the interference of free SIV particles. On day 33 and day 52, these RMs were immunized with saline, HSV-empty, or HSV-sPD1-SIVgag/SIVenv respectively. On day 70, ART treatment in all RMs was discontinued to evaluate the time interval of viral rebound. Samples were collected at different time points to monitor virological and immunological parameters (Figure 4A, table supplement 2). To reduce the impact of individual RM variations, the difference in SIV-specific IFN-γ-secreting SFCs between post-immunization and pre-immunization (ΔSFCs) was used to evaluate the immune response induced by HSV-vectored SIV vaccines. The results showed that SIV Gag-specific ΔSFCs in the ART+HSV-sPD1-SIVgag/SIVenv group were greatly increased when compared with those in the ART+HSV-empty group and ART+saline group (Figure 4B-D). A similar enhancement of SIV Gag-specific TNF-α -secreting CD4+ T and CD8+ T subsets was also verified by ICS assay (Figure 4E). Collectively, these data demonstrated that the HSV-sPD1-SIVgag/SIVenv construct elicited robust SIV-specific T cell immune responses in ART-treated, SIV-infected RMs.
The modified HSV-based constructs effectively reactivated SIV latency in vivo and delayed viral rebound in chronically SIV-infected, ART-treated macaques
Finally, we investigated the therapeutic efficacy of HSV-sPD1-SIVgag/SIVenv in chronically SIV-infected, ART-treated RMs. Consistent with our previous studies, the plasma viral load (VL) in these RMs was effectively suppressed during ART treatment, but rebounded after ART discontinuation. The VL in the ART+saline group promptly rebounded after ART discontinuation, with an average 8.63-fold increase in the rebounded peak VL compared with the pre-ART VL (Figure 5A, D and E). However, plasma VL in the ART+HSV-empty group and the ART+HSV-sPD1-SIVgag/SIVenv group exhibited a delayed rebound interval (Figure 5B-D). Remarkably, there was a lower rebounded peak VL than pre-ART VL in the ART+HSV-sPD1-SIVgag/SIVenv group (average 12.20-fold decrease), while a higher rebounded peak VL than pre-ART VL in the ART+HSV-empty group (average 2.74-fold increase) (Figure 5E). Then, we assessed the potential effect on the latent SIV reservoirs in vivo by administering our modified HSV-based SIV therapeutic constructs in these RMs. Although there were no obvious viral blips observed in these RMs, we found significant suppression of integrated SIV DNA provirus in the ART+HSV-sPD1-SIVgag/SIVenv group. However, the copies of the SIV DNA provirus were significantly improved in the ART+HSV-empty group and ART+saline group (Figure 5F). More interestingly, we next assessed the magnitude of SIV Pol antigen-specific immune responses, which could represent to some extent the level of newly generated virions from the reactivated SIV reservoirs, because SIV Pol antigen was not included in our designed vaccine constructs. Specifically, the Pol-specific SFCs amount on Day 70 (511 SFCs/106 PBMCs, post-vaccination) was higher than that on Day 33 (315 SFCs/106 PBMCs, pre-vaccination) in the ART+HSV-sPD1-SIVgag/SIVenv group. In addition, there was a similar observation in the ART+HSV-empty group. In contrast, the Pol-specific SFCs gradually decreased with the duration of ART treatment in the ART+saline group (Figure 5G). In addition, the CD4+ /CD8+ T cell ratio (Figure 5H) and body weight (Figure 5-figure supplement 5) after treatment were effectively ameliorated in the RMs of the ART+HSV-sPD1-SIVgag/SIVenv group, but not in the ART+HSV-empty group and ART+saline group. Taken together, these findings suggested that the latent SIV reservoirs might be effectively purged because of the effect of simultaneously reactivating viral latency and eliciting SIV-specific immune responses by our modified HSV-based SIV therapeutic constructs, thus resulting in a delayed viral rebound in chronically SIV-infected, ART-treated macaques.
Discussion
To conquer the continuous epidemic of AIDS, exploring novel strategies to render and eliminate HIV latency should stand as a pivotal pursuit. Currently, numerous strategies, including shock and kill, block and lock, chimeric antigen receptor T-cell therapy, therapeutic vaccination, and gene editing, have been extensively investigated to target the latent HIV reservoirs for an HIV functional cure (Deeks, 2012, Yeh and Ho, 2021, Maldini et al., 2020, Herzig et al., 2019, Dash et al., 2023, Dashti et al., 2023, Walker-Sperling et al., 2022). However, there is no safe and effective approach for clinical use in HIV-1 patients yet. In the present study, we occasionally found that the modified HSV-ΔICP34.5-based constructs could reactivate HIV latency more efficiently than wild-type HSV counterpart, which inspired us to develop a proof-of-concept strategy based on a bifunctional HSV-vectored therapeutic vaccine, aiming to simultaneously reactivate viral latency and elicit HIV/SIV-specific immune responses for HIV functional cure. Our results indicated that these modified HSV-based constructs efficiently elicited antigen-specific immune responses in mice and chronically SIV-infected macaques, and further therapeutic efficacy experiments showed that this strategy effectively reactivated SIV latency in vivo and delayed viral rebound in chronically SIV-infected, ART-treated macaques (Figure 6).
The latent HIV proviruses can harbor it into the host genome with a quiescent transcription state, and thus cannot be recognized by immune surveillance or drug killing (Churchill et al., 2016, Pierson et al., 2000). Therefore, it is critical to disrupt viral latency for developing an HIV cure strategy. Based on our experimental data, the mechanism for efficiently reactivating viral latency by the modified HSV-ΔICP34.5-based constructs may involve regulating the IKKα/β-NF-κB pathway and PP1-HSF1 pathway. Indeed, during its replication, HSV can activate the double-stranded RNA-dependent protein kinase (PKR) pathway, and thus phosphorylate the protein translation initiation regulator eIF2α, resulting in the initiation of protein translation (Farassati et al., 2001). Previous studies have shown that the reactivation potential of HSV might be intertwined with NF-κB, Sp1, and other unknown transcription factors by ICP0, ICP4, and ICP27 (Chapman et al., 1991, Amici et al., 2004, Vlach and Pitha, 1992, Mosca et al., 1987b, Golden et al., 1992, Vlach and Pitha, 1993, Mosca et al., 1987a). However, the underlying mechanism by which the ICP34.5-deleted HSV construct can greatly improve the reactivation efficacy of HIV latency remains elusive. ICP34.5 is a neurotoxic factor that can antagonize innate immune responses, including PKR, TANK binding kinase (TBK1) signaling, and Beclin1-mediated apoptosis (He et al., 1997, Manivanh et al., 2017, Orvedahl et al., 2007). ICP34.5 binds to host PP1 and mediates the dephosphorylation of eIF2α, thus allowing protein synthesis and reversing the effects of PKR and host antiviral functions (He et al., 1997, He et al., 1998). In this study, our findings further unveiled an interaction between ICP34.5 and HSF1, resulting in reduced HSF1 phosphorylation via recruitment of PP1α. Interestingly, previous reports indicated that HSF1 could positively regulate HIV gene transcription (Rawat and Mitra, 2011), which is facilitated by its nuclear entry post-phosphorylation and subsequent recruitment of p300 for self-acetylation, along with binding to the HIV-1 LTR. Studies have also shown that HSF1 could further orchestrate p-TEFb recruitment to promote HIV-1 transcriptional elongation (Peng et al., 2020, Lin et al., 2018, Pan et al., 2016b, Pan et al., 2016a). Under stress-induced conditions, phosphorylation triggers the formation of the HSF1 trimer, thus facilitating its nuclear entry to bind to heat shock elements (HSEs) for gene transcription regulation (Bonner et al., 2000, Timmons et al., 2020). Additionally, we also demonstrated that ICP34.5 interacted with IKKα and IKKβ, thereby impeding NF-κB nuclear entry and further curbing HIV latency. Consistently, previous studies have also suggested that ICP34.5 could disrupt the NF-κB pathway and possibly affect the maturation of dendritic cells (Jin et al., 2011). Intriguingly, these findings collectively indicated that ICP34.5 might play an antagonistic role with the reactivation potential of HSV, and thus our modified HSV-ΔICP34.5 constructs reactivate HIV/SIV latency through the release of imprisonment from ICP34.5.
Another observation in this study is that the HSV-sPD1-SIVgag/SIVenv construct elicited robust and persistent SIV-specific T cell immune responses in ART-treated, chronically SIV-infected macaques. Increasing evidence has indicated that HIV-specific cytolytic T lymphocytes (CTLs) can facilitate the suppression of latent viral reservoirs, and thus, the induction of robust and persistent HIV-specific CTL responses is essential for achieving long-term disease-free and transmission-free HIV control (Collins et al., 2020). Featured polyfunctional CD8+ T cells may contribute to HIV elite controllers or long-term non-progressors, a rare proportion of HIV-infected individuals who can spontaneously control viral replication even without ART treatment (Owen et al., 2010, Ferre et al., 2009, O’Connell et al., 2009). In addition, both our previous study and others have demonstrated that strong antigen-specific CD8+ T cell immune responses, especially effector memory CD8+ T cells, were associated with a lower viral load, and in vivo CD8+ lymphocyte depletion with intravenous infusion of anti-CD8 monoclonal antibody could lead to dramatical viral rebound in these vaccinated elite macaques (Perdomo-Celis et al., 2022, Pandrea et al., 2011). Notably, previous studies have shown that HSV-based vaccines expressing HIV/SIV antigen did elicit specific CD8+ T cell immune responses in mice and macaques, but the magnitude was not as strong as other viral vectors (Parker et al., 2007, Murphy et al., 2000, Kaur et al., 2007). Therefore, to further improve its immunogenicity in vivo, some modifications were adopted to optimize the HSV-vectored vaccine. 1) The ICP47 protein, encoded by the US12 gene, can bind to the transporter associated with antigen presentation (TAP) 1/2, inhibiting the transport of viral peptides into the endoplasmic reticulum and the loading of peptides onto nascent major histocompatibility complex (MHC) class I molecules to activate CD8+ T cells (Orr et al., 2005). Therefore, the ICP47 gene was deleted from our developed HSV vector. 2) Negative immunoregulatory molecules, including PD1, TIM-3, and LAG-3, are usually involved in the pathogenesis of HIV infection, as well as in chronically SIV-infected macaques. Among them, PD1 upregulation can result in the exhaustion and dysfunction of CD8+ T cells (Trautmann et al., 2006). In addition, PD1 expression on memory CD4+ T cells might be linked with HIV latency. In this study, we modified the SIV antigen by fusing to soluble PD1 (sPD1), which can block the PD1/PDL1 pathway by competitively binding with PDL1 and thus improve HIV/SIV vaccine-induced CD8+ T cell immune responses (Zhou et al., 2013, Wu et al., 2022, Pan et al., 2018, Xiao et al., 2014).
Although promising, there are still some limitations to our study. First, this is a pilot study with relatively small numbers of RMs, and future studies with a larger number of animals can be conducted to better verify our strategy. Second, the HSV-sPD1-SIVgag/SIVenv vaccine resulted in delayed viral rebound and a lower peak viral load post-rebound than pre-ART treatment but did not completely suppress SIV virus rebound in this study, which may be attributed to suboptimal doses and treatment, implying that we should further optimize this regimen for eventually achieving an HIV functional cure in future studies. Taken together, these findings demonstrated that our modified HSV-ΔICP34.5-based constructs potentially reactivated HIV/SIV latency by modulating the IKKα/β-NF-κB pathway and PP1-HSF1 pathway, and thereby we developed a proof-of-concept HIV functional cure strategy based on a bifunctional HSV-vectored therapeutic vaccine, which can provide insights into the rational design of novel strategies for pursuing an HIV functional cure.
Methods
Mouse ethics statement and vaccination
Female BALB/c mice, aged six to eight weeks, were procured from the Experimental Animal Center of Sun Yat-sen University. A total of twenty-five mice were randomly divided into five groups to evaluate the immunogenicity of the recombinant HSV-vector-based SIV vaccine. During the initial week, each mouse was subcutaneously administered a vaccination of 1×106 PFU of the respective recombinant HSV-vector vaccines (HSV-empty, HSV-sPD1, HSV-SIVgag, HSV-sPD1-SIVgag, HSV-SIVenv). Following a two-week interval, a booster vaccination was administered via the subcutaneous route using 2×106 PFU of recombinant HSV-vector vaccines. The subsequent assessment of the immune response involved ELISpot and intracellular cytokine staining (ICS) assays in accordance with the vaccination schedule.
Ethics statement and vaccination of macaques
A total of 9 chronically SIVmac239-infected rhesus macaques (RMs) were included in this study. All RMs received ART treatment (FTC/6.7 mg/kg/once daily, PMPA/10 mg/kg/once daily) for a duration of 33 days. The RMs were allocated into three groups based on their baseline plasma SIV viral loads (VL): ART + saline (n=3) as the control group, ART+ HSV-empty (n=3) as the sham group, and ART+ HSV-sPD1-SIVgag/SIVenv (n=3) as the vaccinated group. On day 0, all RMs received ART treatment. Once the VL dropped below the limit of detection (1×102 copies/mL), the vaccinated group and sham group were primed with a subcutaneous vaccination of 1×107 PFU HSV-sPD1-SIVgag/SIVenv or HSV-empty, respectively, while the control group received an injection of 0.9% saline. After three weeks of the prime vaccination, the vaccinated group and sham group RMs received a subcutaneous booster vaccination of 5×107 PFU HSV-sPD1-SIVgag/SIVenv or HSV-empty, respectively. After two weeks of booster vaccination, the ART treatment for all RMs was interrupted. The immune response was evaluated by IFN-γ ELISpot and ICS assays. Plasma viral load was regularly monitored throughout the studied period.
Peptide pools
The peptide pools, encompassing the complete sequences of SIV Gag, Env, and Pol proteins, comprising 15 amino acids with 11 overlaps, were generously provided by the HIV Reagent Program, National Institutes of Health (NIH), USA. Gag pools comprise 125 peptides, while Env and Pol pools are subdivided into Env1 (109 peptides) and Env2 (109 peptides) pools, as well as Pol1 (131 peptides) and Pol2 (132 peptides) pools. These peptide pools were dissolved in dimethyl sulfoxide (DMSO, Sigma) at a concentration of 0.4 mg/ peptide/mL for subsequent immunological assays.
Construction of recombinant HSV
For the generation of recombinant HSV-vector-based vaccines, we implemented modifications at the ICP34.5 loci through homologous recombination within the BAC-HSV-1 system. Specifically, double copies of the ICP34.5 and ICP47 genes were either deleted or inserted into the respective counterparts: sPD1, SIVgag, sPD1-SIVgag, and SIVenv genes. The sPD1-SIVgag gene was created by fusing the N-terminal region of mouse soluble PD1 (sPD1) with the C-terminal segment of SIVgag, connected by a GGGSGGG linker, which was engineered through overlapping PCR.
IFN-γ ELISpot assay
The IFN-γ-ELISpot assay was conducted in accordance with our previous study (Sun et al., 2010). In the mouse experiment, 2.5×105 freshly isolated mouse spleen lymphocytes were simulated with SIV Gag, Env1, and Env2 peptide pools. In the monkey experiment, 2×105 peripheral blood mononuclear cells (PBMCs) were seeded and simulated with the SIV Gag, Env, and Pol peptide pools. Mock stimulation utilized DMSO (Sigma), while concanavalin A (ConA, 10 μg/mL) was employed as a positive control. Spot quantification was performed using an ELISpot reader (Mabtech), and peptide-specific spot counts were determined by subtracting the spots from mock stimulation.
Intracellular cytokine staining (ICS)
The ICS assay was performed as described previously (Wu et al., 2022). In the mouse experiment, 2×106 freshly isolated mouse spleen lymphocytes were stimulated with SIV Gag, Env1, and Env2 peptide pools. For the monkey experiment, 2×106 PBMCs were seeded and simulated with the SIV Gag, Env, and Pol peptide pools. DMSO and PMA (Thermo Scientific) plus ionomycin were used as the mock and positive controls, respectively. Data analysis was performed using FlowJo software (version 10.8.1), and the antibodies used are listed in table supplement 3. The frequencies of cytokines produced from peptide-specific cells were analyzed by subtracting mock stimulation.
SIV viral RNA and DNA copy assays and absolute T cell count
Absolute T cell count and the levels of plasma mRNA and SIV total DNA were quantified as described previously (Wu et al., 2022). Plasma viral RNA copy numbers were determined via SYBR green-based real-time quantitative PCR (Takara), using SIV gag-specific primers (table supplement 4). Viral RNA copy numbers were calculated based on the standard curve established using SIVmac239 gag standards. The lower limit of detection for this assay was 100 copies/mL of plasma. Total cellular DNA was extracted from approximately 0.5 to 5 million cells using a QIAamp DNA Blood Minikit (Qiagen). PCR assays were performed with 200 ng samples of DNA, and SIV viral DNA was quantified using a pair of primers targeting a conserved region of the SIV gag gene, as previously described. Quantitation was performed by comparing the results to the standard curve of SIV gag copies.
Plasmids, cells, and viruses
pVAX-Myc-PDL1, pVAX-Flag-ICP34.5, pVAX-Myc-HSF1, pVAX-HA-PP1α: full-length mouse PDL1, full-length HSV-1 ICP34.5, and full-length human HSF1 and human PP1α with N or C-terminal Tag were cloned into the pVAX vector. pVAX-empty, pcDNA3.1-IKKα, and pcDNA3.1-IKKβ plasmids were stored in our laboratory. pVAX-empty was used as a mock transfection in our study.
293T cells (from the embryonic kidney of a female human fetus), Vero cells (from the kidney of a female normal adult African green monkey), and Hela cells (from the cervical cancer cells of an African American woman) were cultured in complete Dulbecco’s modified Eagle’s medium (DMEM, Gibco) containing 10% fetal bovine serum (FBS, Gibco) and 1% penicillin/streptomycin (Gibco) at 37°C in an atmosphere of 5% CO2. The J-Lat 10.6 cells (Jurkat cells contain the HIV-1 full-length genome whose Env was frameshifted and inserted with GFP in place of Nef) and the HIV-1 latently infected CD4+ CEM cells ACH-2 (A3.01 cell integrated HIV-1 proviral DNA) were cultured in complete RPIM640 (Gibco) containing 10% FBS and 1% penicillin/streptomycin at 37°C in an atmosphere of 5% CO2. J-Lat 10.6-ICP34.5 cells were constructed in our laboratory.
The HSV-1 (McKrae) and HSV-1 (F) strains were stored in our laboratory. HSV-1 (17 strain) was rescued from pBAC-GFP-HSV in Vero cells. HSV-ΔICP34.5 was rescued from pBAC-GFP-HSV-ΔICP34.5 (with double copies of ICP34.5 deleted) in Vero cells.
RT-qPCR
RT-qPCR was performed as described in our previous study (Zhao et al., 2022). Data were normalized to β-actin. The primer sequences are listed in Supplemental Table 4. Fold changes in the threshold cycle (Ct) values were calculated using the 2−ΔΔCt method.
Chromatin immunoprecipitation (ChIP) assay
ChIP analysis was conducted using the SimpleChIP Enzymatic Chromatin IP kit (Agarose Beads) (CST), following the manufacturer’s instructions. Quantitative real-time PCR was employed for detecting the LTR sequence. The sequences of primers used in the LTR ChIP are listed in Supplemental Table 4. % Input= 2% × 2[(ct)2% input sample (ct) IP sample].
Co-immunoprecipitation (Co-IP)
Cells were harvested and subjected to Co-IP assay, following the protocol outlined in our previous study (Zhao et al., 2022).
Western blotting analysis
Nuclear and cytoplasmic proteins were extracted by kits following the manufacturer’s instructions (Beyotime). The Western blotting assay was performed as previously described (Zhao et al., 2022).
Statistical analysis
GraphPad Prism 8.0 (GraphPad Software, San Diego, California) was used for statistical analysis. For intragroup direct comparisons, Student’s unpaired two-tailed t test was performed to analyze significant differences. For comparisons of multiple groups, one-way ANOVAs were performed. Significance levels are indicated as *P< 0.05, ** P< 0.01, *** P< 0.001, **** P< 0.0001.
Study approval
Mice experiment was approved by the Laboratory Animal Ethics Committee guidelines at Sun Yat-sen University (approval number: SYSU-IACUC-2021-000185). Chinese rhesus macaques (Macaca mulatta) were housed at the Landau Animal Experimental Center, Guangdong Landau Biotechnology Co., Ltd. (approval number: N2021101).
Acknowledgements
We appreciate the staff at the Animal Center of GIBH for their excellent technical assistance. We thank all other members of our group for their helpful advice and discussion to improve this project. We also appreciate the NIH AIDS Research and Reference Reagent Program for providing SIV peptide pools.
Additional information
Competing interests
The authors have declared that no conflict of interest exists.
Funding
This project was supported by National Natural Science Foundation of China (81971927, 82271786, 32370171), National Key R&D Program of China (2022YFE0203100, 2021YFC2300103).
Author Contributions
All authors were involved in drafting or critically revising the manuscript for important intellectual content, and all authors approved the final version for publication. CS conceived the project and provided the main funding. CS and LC designed the experiments and reviewed the manuscript. ZW, PL, YY, and CW performed most of the experiments and analyzed the data. ZW, PL, YY, CW, ML, HW, MS, YH, and MC established the animal models and performed animal experiments. ZW and CS interpreted the data and wrote the manuscript.
Additional files
Supplementary files
Figure S1-S5. Table S1-S4.
Data Availability Statement
Source data contain the numerical data used to generate the figures.
References
- Activation of I kappa b kinase by herpes simplex virus type 1. A novel target for anti-herpetic therapyJ Biol Chem 276:28759–28766https://doi.org/10.1074/jbc.M103408200
- Inhibition of herpesvirus-induced HIV-1 replication by cyclopentenone prostaglandins: role of Ikappab kinase (Ikk)Aids 18:1271–1280https://doi.org/10.1097/00002030-200406180-00005
- Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latencyJ Clin Invest 127:3126–3135https://doi.org/10.1172/jci92684
- Eradicating HIV-1 infection: seeking to clear a persistent pathogenNat Rev Microbiol 12:750–764https://doi.org/10.1038/nrmicro3352
- Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcriptionProc Natl Acad Sci U S A 104:13690–13695https://doi.org/10.1073/pnas.0705053104
- Structural analysis of yeast HSF by site-specific crosslinkingJ Mol Biol 302:581–592https://doi.org/10.1006/jmbi.2000.4096
- Herpes simplex virus type 1 can either suppress or enhance human immunodeficiency virus type 1 replication in CD4-positive T lymphocytesJ Med Virol 70:163–170https://doi.org/10.1002/jmv.10350
- A recombinant HIV provirus is synergistically activated by the HIV Tat protein and the HSV IE1 protein but not by the HSV IE3 proteinAids 5
- HIV reservoirs: what, where and how to target themNat Rev Microbiol 14:55–60https://doi.org/10.1038/nrmicro.2015.5
- CD8(+) T cells in HIV control, cure and preventionNat Rev Immunol 20:471–482https://doi.org/10.1038/s41577-020-0274-9
- CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized miceProc Natl Acad Sci U S A 120https://doi.org/10.1073/pnas.2217887120
- AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaquesNat Med https://doi.org/10.1038/s41591-023-02570-7
- HIV: Shock and killNature 487:439–440https://doi.org/10.1038/487439a
- Oncogenes in Ras signalling pathway dictate host-cell permisSIVeness to herpes simplex virus 1Nat Cell Biol 3:745–750https://doi.org/10.1038/35087061
- Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune controlBlood 113:3978–3989https://doi.org/10.1182/blood-2008-10-182709
- Activation of human immunodeficiency virus by herpes simplex virusJ Infect Dis 166:494–499https://doi.org/10.1093/infdis/166.3.494
- The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded Rna-activated protein kinaseProc Natl Acad Sci U S A 94:843–848https://doi.org/10.1073/pnas.94.3.843
- The gamma134.5 protein of herpes simplex virus 1 has the structural and functional attributes of a protein phosphatase 1 regulatory subunit and is present in a high molecular weight complex with the enzyme in infected cellsJ Biol Chem 273:20737–20743https://doi.org/10.1074/jbc.273.33.20737
- Arsenic trioxide-induced apoptosis contributes to suppression of viral reservoir in SIV-infected rhesus macaquesMicrobiol Spectr: e 52523https://doi.org/10.1128/spectrum.00525-23
- Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1Lancet 343:255–258https://doi.org/10.1016/s0140-6736(94)91110-x
- Attacking Latent HIV with convertiblecar-T Cells, a Highly Adaptable Killing PlatformCell 179:880–894https://doi.org/10.1016/j.cell.2019.10.002
- A herpesvirus virulence factor inhibits dendritic cell maturation through protein phosphatase 1 and Ikappa B kinaseJ Virol 85:3397–3407https://doi.org/10.1128/jvi.02373-10
- Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virusVirology 357:199–214https://doi.org/10.1016/j.virol.2006.08.007
- Getting the “Kill” into “Shock and Kill”: Strategies to Eliminate Latent HIVCell Host Microbe 23:14–26https://doi.org/10.1016/j.chom.2017.12.004
- Depletion of latent HIV-1 infection in vivo: a proof-of-concept studyLancet 366:549–555https://doi.org/10.1016/s0140-6736(05)67098-5
- Role of HIV-specific CD8(+) T cells in pediatric HIV cure strategies after widespread early viral escapeJ Exp Med 214:3239–3261https://doi.org/10.1084/jem.20162123
- ICP34.5 protein of herpes simplex virus facilitates the initiation of protein translation by bridging eukaryotic initiation factor 2alpha (eIF2alpha) and protein phosphatase 1J Biol Chem 286:24785–24792https://doi.org/10.1074/jbc.M111.232439
- The Bet bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivationNucleic Acids Res 41:277–287https://doi.org/10.1093/nar/gks976
- PR-957, a selective immunoproteasome inhibitor, reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1Biochem Pharmacol 156:511–523https://doi.org/10.1016/j.bcp.2018.08.042
- Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysisLancet Infect Dis 17:1303–1316https://doi.org/10.1016/s1473-3099(17)30405-x
- Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivoNat Med 26:1776–1787https://doi.org/10.1038/s41591-020-1039-5
- Role of Herpes Simplex Virus 1 γ34.5 in the Regulation of IRF3 SignalingJ Virol 91https://doi.org/10.1128/jvi.01156-17
- Activation of human immunodeficiency virus by herpesvirus infection: identification of a region within the long terminal repeat that responds to a trans-acting factor encoded by herpes simplex virus 1Proc Natl Acad Sci U S A 84:7408–7412https://doi.org/10.1073/pnas.84.21.7408
- Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virusNature 325:67–70https://doi.org/10.1038/325067a0
- Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virusJ Virol 74:7745–7754https://doi.org/10.1128/jvi.74.17.7745-7754.2000
- Elucidating the elite: mechanisms of control in HIV-1 infectionTrends Pharmacol Sci 30:631–637https://doi.org/10.1016/j.tips.2009.09.005
- Inhibition of MHC class I is a virulence factor in herpes simplex virus infection of micePLos Pathog 1https://doi.org/10.1371/journal.ppat.0010007
- HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy proteinCell Host Microbe 1:23–35https://doi.org/10.1016/j.chom.2006.12.001
- HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responsesAids 24:1095–1105https://doi.org/10.1097/Qad.0b013e3283377a1e
- Immune Protection of SIV Challenge by PD-1 Blockade During Vaccination in Rhesus MonkeysFront Immunol 9https://doi.org/10.3389/fimmu.2018.02415
- Heat Shock Protein 90 Facilitates Latent HIV Reactivation through Maintaining the Function of Positive Transcriptional Elongation Factor b (p-TEFb) under Proteasome InhibitionJ Biol Chem 291:26177–26187https://doi.org/10.1074/jbc.M116.743906
- Heat Shock Factor 1 Mediates Latent HIV ReactivationSci Rep 6https://doi.org/10.1038/srep26294
- Functional cure of SIVagm infection in rhesus macaques results in complete recovery of CD4+ T cells and is reverted by CD8+ cell depletionPLos Pathog 7https://doi.org/10.1371/journal.ppat.1002170
- HIV-1(89.6) Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in miceVaccine 25:6764–6773https://doi.org/10.1016/j.vaccine.2007.06.064
- Thiostrepton Reactivates Latent HIV-1 through the p-TEFb and NF-κb Pathways Mediated by Heat Shock ResponseAntimicrob Agents Chemother 64https://doi.org/10.1128/aac.02328-19
- Reprogramming dysfunctional CD8+ T cells to promote properties associated with natural HIV controlJ Clin Invest 132https://doi.org/10.1172/jci157549
- HSV-2 triggers upregulation of MALAT1 in CD4+ T cells and promotes HIV latency reversalJ Clin Invest 133https://doi.org/10.1172/jci164317
- Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapyAnnu Rev Immunol 18:665–708https://doi.org/10.1146/annurev.immunol.18.1.665
- First Oncolytic Viral Therapy for MelanomaCancer Discov 6https://doi.org/10.1158/2159-8290.Cd-nb2015-158
- Cellular heat shock factor 1 positively regulates human immunodeficiency virus-1 gene expression and replication by two distinct pathwaysNucleic Acids Res 39:5879–5892https://doi.org/10.1093/nar/gkr198
- Induction of balance and breadth in the immune response is beneficial for the control of SIVmac239 replication in rhesus monkeysJ Infect 60:371–381https://doi.org/10.1016/j.jinf.2010.03.005
- HSF1 inhibition attenuates HIV-1 latency reversal mediated by several candidate LRAs In Vitro and Ex VivoProc Natl Acad Sci U S A 117:15763–15771https://doi.org/10.1073/pnas.1916290117
- Upregulation of Pd-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunctionNat Med 12:1198–1202https://doi.org/10.1038/nm1482
- Herpes simplex virus type 1-mediated induction of human immunodeficiency virus type 1 provirus correlates with binding of nuclear proteins to the NF-kappa B enhancer and leader sequenceJ Virol 66:3616–3623https://doi.org/10.1128/jvi.66.6.3616-3623.1992
- Differential contribution of herpes simplex virus type 1 gene products and cellular factors to the activation of human immunodeficiency virus type 1 provirusJ Virol 67:4427–4431https://doi.org/10.1128/jvi.67.7.4427-4431.1993
- Therapeutic efficacy of combined active and pasSIVe immunization in ART-suppressed, SHIV-infected rhesus macaquesNat Commun 13https://doi.org/10.1038/s41467-022-31196-5
- Exacerbated AIDS Progression by PD-1 Blockade during Therapeutic Vaccination in Chronically Simian Immunodeficiency Virus-Infected Rhesus Macaques after Interruption of Antiretroviral TherapyJ Virol 96https://doi.org/10.1128/Jvi.01785-21
- Modulation of Antiviral Immunity and Therapeutic Efficacy by 25-Hydroxycholesterol in Chronically SIV-Infected, ART-Treated Rhesus MacaquesVirol Sin 36:1197–1209https://doi.org/10.1007/s12250-021-00407-6
- Enhancement of SIV-specific cell mediated immune responses by co-administration of soluble PD-1 and Tim-3 as molecular adjuvants in miceHum Vaccin Immunother 10:724–733https://doi.org/10.4161/hv.27340
- PARP1 Might Substitute HSF1 to Reactivate Latent HIV-1 by Binding to Heat Shock ElementCells 11https://doi.org/10.3390/cells11152331
- Arsenic Trioxide Impacts Viral Latency and Delays Viral Rebound after Termination of ART in Chronically SIV-Infected MacaquesAdv Sci (Weinh) 6https://doi.org/10.1002/advs.201900319
- Shock-and-kill versus block-and-lock: Targeting the fluctuating and heterogeneous HIV-1 gene expressionProc Natl Acad Sci U S A 118https://doi.org/10.1073/pnas.2103692118
- Resveratrol Reactivates Latent HIV through Increasing Histone Acetylation and Activating Heat Shock Factor 1J Agric Food Chem 65:4384–4394https://doi.org/10.1021/acs.jafc.7b00418
- Kynurenine-3-monooxygenase (KMO) broadly inhibits viral infections via triggering Nmdar/Ca2+ influx and Camkii/ IRF3-mediated IFN-beta productionPLos Pathog 18https://doi.org/10.1371/journal.ppat.1010366
- PD1-based DNA vaccine amplifies HIV-1 Gag-specific CD8+ T cells in miceJ Clin Invest 123:2629–2642https://doi.org/10.1172/jci64704
Article and author information
Author information
Version history
- Sent for peer review:
- Preprint posted:
- Reviewed Preprint version 1:
Copyright
© 2024, Wen et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
- views
- 181
- downloads
- 10
- citations
- 0
Views, downloads and citations are aggregated across all versions of this paper published by eLife.